Despite the downturn in lab demand and glut of life science space in Greater Boston, Beacon Capital is seeking to add a second, 500,000-square-foot building next to its same-size 2 Harbor St. building, now nearing completion without a tenant commitment.

Why would a developer plow forward with a large, seemingly-spec lab development when the market is already flooded with unleased space? Beacon Capital declined to comment on a potential tenant, but at a recent public meeting, Beacon Capital Managing Director Eric Ewer said the firm has its eye on a specific target.

And who might that be? Likely it’s Vertex Pharmaceuticals, which is publicly contemplating moving its big headquarters from Fan Pier.

What else is on tap today?

Show me the data!

What’s the single-family mortgage market doing?

What did I miss?

Here’s what you might have missed in Sunday’s newsletter. Not a B&T subscriber? Fix that here.

The B&T Daily: April 23, 2024

by James Sanna time to read: 1 min